NLRP3 and metabolic dysfunction-associated steatotic liver disease: Signals of benefit with CCR2/CCR5 antagonism (CVC), polyphenolic antioxidants and gut–liver axis modulators in ALD, alongside CASP inhibitors (such as GS‐9450, Emricasan, and VX‐166), and NLRP3‐targeted approaches (MCC950, Antcin A, dieckol, vitamin D; lncRNA GAS5–miR‐28a‐5p axis) in MASLD, underscore translational relevance.